Read our latest updates & insights

mAbxience announced it will install an ABEC 4,000L CSR bioreactor at its site in Leon, Spain. The system is expected to be installed within months, and will boost mAbxience’s biosimilar and CDMO manufacturing capacity.

EirGenix announced that its Ph III clinical trial of EG12014 (proposed trastuzumab biosimilar) has met its primary endpoint. EirGenix announced that EG12014 has shown equivalent efficacy to Herceptin®, and demonstrated a comparable safety profile.

The Korea Herald reported that Celltrion’s Herzuma® (biosimilar trastuzumab) reached a 44% market share in Japan last year.

Reuters reported that Pfizer will stop producing biosimilar products in China and will sell an intended manufacturing site in Hangzhou to WuXi Biologics.

Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) announced it has filed a Form 10 registration statement with the US Securities and Exchange Commission in relation to its intended biosimilars and women’s health spinoff, Organon. Merck &a...

Alvotech announced it has completed a second round of its US$100 million private placement.  In the first round, Alvotech raised US$65 million, including investments from Korea’s Shinhan, US’ Baxter Healthcare SA, and Germany’s ATHOS.

Korea Biomedical Review reported that Samsung Bioepis has entered an agreement with Yuhan Corp for the commercialisation of Adalloce™ (biosimilar adalimumab) in South Korea. Adalloce™ is marketed in Europe as Imraldi®.